Claims for Patent: 7,989,452

Summary for Patent: 7,989,452

Title:	Stable hydrazalazine pharmaceutical compositions
Abstract:	The present invention relates to stable and highly purified stable hydralazine hydrochloride compositions and stable hydralazine-containing pharmaceutical compositions. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration is described comprising a therapeutically effective dose of hydralazine hydrochloride in a pharmaceutically acceptable carrier or diluent wherein the hydralazine hydrochloride is essentially free of phthalazines, hydrazine and metal ions. In addition, a stable sterile aqueous pharmaceutical composition comprising hydralazine hydrochloride in a pharmaceutically acceptable salt or diluent is described that is colorless and has no visible particulate matter.
Inventor(s):	Nelson; Deanna J. (Cary, NC), Barbeau; Donald (Evanston, IL)
Assignee:	Bioniche Teoranta (Galway, IE)
Application Number:	10/745,232
Patent Claims:	1. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration comprising a therapeutically effective dose of a hydralazine hydrochloride composition in a pharmaceutically acceptable carrier or diluent, the aqueous injectable pharmaceutical composition further comprising polyethylene glycol and sterile water for injection, wherein said hydralazine hydrochloride composition comprises hydralazine hydrochloride, less than about 1% by weight of phthalazine compounds, less than about 0.0005% hydrazine by weight, and less than about 15 parts per million metal ions, and wherein said pharmaceutical composition has no visible particulate matter 30 months after manufacture, said pharmaceutical composition has less than 6000 10 micron particles per container 30 months after manufacture and said pharmaceutical composition has less than 600 25 micron particles per container 30 months after manufacture. 2. The composition of claim 1 wherein said injectable pharmaceutical composition is in a sealed container. 3. The composition of claim 1 wherein the therapeutically effective dose is from about 5 to about 20 mg and the concentration of hydralazine hydrochloride is about 5 mg/ml. 4. The composition of claim 1 wherein the hydralazine hydrochloride concentration is from about 3.0 to about 20 mg/ml. 5. The composition of claim 1 wherein the hydralazine hydrochloride concentration is from about 3.0 to about 5.0 mg/ml. 6. The composition of claim 1 wherein the polyethylene glycol is essentially free of ethylene oxide and ethylene glycol. 7. A sterile aqueous pharmaceutical composition comprising a hydralazine hydrochloride composition comprising from about 3 to about 20 mg/ml hydralazine hydrochloride, the aqueous pharmaceutical composition further comprising methyl paraben, propyl paraben and polyethylene glycol in sterile water for injection, wherein the polyethylene glycol has an average molecular weight of 200, 400, 600, 1,000, 3,000, 5,000, or 10,000 Daltons and is essentially free of ethylene oxide and ethylene glycol, wherein said hydralazine hydrochloride composition comprises the hydralazine hydrochloride, less than about 1% by weight of phthalazine compounds, less than about 0.0005% hydrazine by weight, and less than about 15 parts per million metal ions. 8. The composition of claim 7 wherein the concentration of hydralazine hydrochloride is from about 3 to about 5 mg/ml. 9. The composition of claim 8 wherein the concentration of hydralazine hydrochloride is about 5 mg/ml. 10. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration in a sealed container comprising a hydralazine hydrochloride composition comprising from about 0.5 to about 40 mg/ml hydralazine hydrochloride in a pharmaceutically acceptable carrier or diluent wherein said hydralazine hydrochloride composition comprises hydralazine hydrochloride, less than about 1% by weight of phthalazine compounds, less than about 0.0005% hydrazine by weight, and less than about 15 parts per million metal ions, said injectable pharmaceutical composition having no visible particulate matter after storage at 40.degree. C. at 118 days after manufacture, less than 3,000 10 micron particles per container after storage at 40.degree. C. at 118 days after manufacture, and less than 200 25 micron particles per container after storage at 40.degree. C. at 118 days after manufacture. 11. The composition of claim 10 wherein the concentration of hydralazine hydrochloride is about 5 mg/ml. 12. The composition of claim 10 wherein said pharmaceutical composition has no visible particulate matter after storage at 40.degree. C. at 118 days after manufacture, about 2370 or fewer 10 micron particles per container after storage at 40.degree. C. at 118 days after manufacture, and about 160 or fewer 25 micron particles per container after storage at 40.degree. C. at 118 days after manufacture. 13. The composition of claim 12 having about 5 mg/ml hydralazine hydrochloride after storage at 40.degree. C. at 118 days after manufacture. 14. A sterile aqueous pharmaceutical composition comprising about 5 mg/ml hydralazine hydrochloride, about 0.1625 mg/ml methyl paraben, about 0.0875 mg/ml propyl paraben and 100 mg/ml polyethylene glycol in sterile water for injection, wherein the polyethylene glycol has an average molecular weight of 200, 400, 600, 1,000, 3,000, 5,000, or 10,000 Daltons and is essentially free of ethylene oxide and ethylene glycol, wherein said aqueous pharmaceutical composition comprises less than about 1% by weight of phthalazine compounds, less than about 0.0005% hydrazine by weight, and less than about 15 parts per million metal ions. 15. The composition of claim 7, wherein the methyl paraben is at a concentration of about 0.1625 mg/ml and the propyl paraben is at a concentration of about 0.0875 mg/ml. 16. The composition of claim 7, wherein the methyl paraben is at a concentration of about 0.325 mg/ml and the propyl paraben is at a concentration of about 0.175 mg/ml. 17. The composition of claim 7, wherein the polyethylene glycol is at a concentration of about 100 mg/ml.

Details for Patent 7,989,452

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22